AI Engines For more Details: Perplexity Kagi Labs You
Motion Sickness: Cinnarizine is effective in preventing and relieving symptoms of motion sickness, including nausea, vomiting, dizziness, and vertigo, commonly experienced during travel by car, boat, or airplane. It works by blocking histamine H1 receptors in the vestibular system and the vomiting center of the brain, thereby reducing the sensitivity of the inner ear to motion stimuli and decreasing the likelihood of motion sickness symptoms.
Vertigo: Cinnarizine is also used to treat vertigo, a sensation of spinning or dizziness often associated with inner ear disorders such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Meniere's disease. By exerting its antihistamine and calcium channel blocking effects, cinnarizine helps alleviate vertigo symptoms and improve balance and stability in affected individuals.
Peripheral Vestibular Disorders: Cinnarizine may be prescribed for individuals with peripheral vestibular disorders characterized by disturbances in balance and spatial orientation, such as labyrinthitis, vestibular neuronitis, and vestibular migraine. It can help reduce vertigo attacks and associated symptoms, allowing patients to better cope with their condition and maintain daily activities.
Inner Ear Disorders: Cinnarizine is sometimes used off-label in the treatment of various inner ear disorders, including tinnitus (ringing in the ears) and hearing loss associated with vestibular dysfunction. Although its efficacy in these conditions is less well-established, cinnarizine may provide symptomatic relief by modulating blood flow and reducing the hyperexcitability of the vestibular system.
Ménière's Disease: Cinnarizine may be prescribed as part of the management plan for individuals with Ménière's disease, a chronic inner ear disorder characterized by recurrent episodes of vertigo, sensorineural hearing loss, tinnitus, and a sensation of fullness or pressure in the affected ear. Cinnarizine can help alleviate vertigo attacks and associated symptoms, although its long-term efficacy in preventing disease progression is uncertain.
Side Effects: Common side effects of cinnarizine may include drowsiness, dry mouth, blurred vision, constipation, and gastrointestinal disturbances. These side effects are usually mild and transient, and they may diminish with continued use or dose adjustment. Cinnarizine may cause drowsiness or impair alertness, so individuals should avoid activities that require mental alertness or coordination, such as driving or operating heavy machinery, until they know how the medication affects them.
Contraindications: Cinnarizine is contraindicated in individuals with a known hypersensitivity to the medication or any of its components, as well as those with Parkinson's disease, hypotension, severe heart failure, or severe hepatic impairment. It should be used with caution in elderly patients and those with glaucoma, urinary retention, or prostatic hypertrophy.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0.5 | -0.5 | |
ADHD | 5.5 | 1 | 4.5 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.1 | 9 |
Allergic Rhinitis (Hay Fever) | 1.9 | 2.3 | -0.21 |
Allergies | 6.4 | 2.5 | 1.56 |
Allergy to milk products | 1.6 | 0.9 | 0.78 |
Alopecia (Hair Loss) | 1.5 | 1.5 | |
Alzheimer's disease | 2.6 | 6.1 | -1.35 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1 | 2.3 |
Ankylosing spondylitis | 4.6 | 1.8 | 1.56 |
Anorexia Nervosa | 0.1 | 2.7 | -26 |
Antiphospholipid syndrome (APS) | 3 | 0.1 | 29 |
Asthma | 1.7 | 0.7 | 1.43 |
Atherosclerosis | 1.2 | 2.3 | -0.92 |
Atrial fibrillation | 4 | 2.2 | 0.82 |
Autism | 11.8 | 10.6 | 0.11 |
Barrett esophagus cancer | 0.2 | 0.3 | -0.5 |
benign prostatic hyperplasia | 0.4 | 0.4 | |
Bipolar Disorder | 1.1 | 1.9 | -0.73 |
Brain Trauma | 1 | 0.7 | 0.43 |
Carcinoma | 4.1 | 2.8 | 0.46 |
Celiac Disease | 2.8 | 4.1 | -0.46 |
Cerebral Palsy | 1.3 | 1.5 | -0.15 |
Chronic Fatigue Syndrome | 7.1 | 7.2 | -0.01 |
Chronic Kidney Disease | 3 | 2.8 | 0.07 |
Chronic Lyme | 0.7 | -0.7 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 1.5 | 0.2 |
Chronic Urticaria (Hives) | 2 | 1.2 | 0.67 |
Coagulation / Micro clot triggering bacteria | 1.6 | 1.5 | 0.07 |
Colorectal Cancer | 3.7 | 1.4 | 1.64 |
Constipation | 2.1 | 1 | 1.1 |
Coronary artery disease | 1.9 | 1.2 | 0.58 |
COVID-19 | 13.7 | 17 | -0.24 |
Crohn's Disease | 7.9 | 6.3 | 0.25 |
cystic fibrosis | 1.1 | 1.2 | -0.09 |
deep vein thrombosis | 1.1 | 1 | 0.1 |
Depression | 10.6 | 9.5 | 0.12 |
Dermatomyositis | 0.3 | 0.5 | -0.67 |
Eczema | 1.4 | 1.8 | -0.29 |
Endometriosis | 3.8 | 1.2 | 2.17 |
Eosinophilic Esophagitis | 0.2 | -0.2 | |
Epilepsy | 2.7 | 1.7 | 0.59 |
Fibromyalgia | 2.9 | 3.7 | -0.28 |
Functional constipation / chronic idiopathic constipation | 7.1 | 4.4 | 0.61 |
gallstone disease (gsd) | 2.3 | 0.9 | 1.56 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.3 | 0.15 |
Generalized anxiety disorder | 2.4 | 2.5 | -0.04 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.3 | 2 | -0.54 |
Halitosis | 0.5 | 0.3 | 0.67 |
Hashimoto's thyroiditis | 3.2 | 0.8 | 3 |
Hidradenitis Suppurativa | 0.4 | 0.2 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.7 | 1.4 | 2.36 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
hyperglycemia | 0.4 | 1.3 | -2.25 |
Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 2.2 | 4.4 | -1 |
Hypothyroidism | 1.9 | -1.9 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 6.1 | -6.1 | |
Inflammatory Bowel Disease | 5.2 | 9.1 | -0.75 |
Insomnia | 1.1 | 1.2 | -0.09 |
Intelligence | 1.6 | 0.9 | 0.78 |
Intracranial aneurysms | 1.1 | 0.5 | 1.2 |
Irritable Bowel Syndrome | 4.4 | 4.7 | -0.07 |
Liver Cirrhosis | 4.6 | 3.4 | 0.35 |
Long COVID | 9.9 | 11 | -0.11 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 0.7 | 1.2 | -0.71 |
ME/CFS with IBS | 1.6 | 3.7 | -1.31 |
ME/CFS without IBS | 3 | 2.2 | 0.36 |
Menopause | 2.7 | 2.7 | |
Metabolic Syndrome | 8.4 | 8.1 | 0.04 |
Mood Disorders | 13 | 10 | 0.3 |
multiple chemical sensitivity [MCS] | 1 | 0.5 | 1 |
Multiple Sclerosis | 5.8 | 5.4 | 0.07 |
Multiple system atrophy (MSA) | 0.8 | 1.2 | -0.5 |
Neuropathy (all types) | 0.8 | 0.4 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.4 | 6.3 | -0.85 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 9.2 | 4.4 | 1.09 |
obsessive-compulsive disorder | 7.9 | 5.6 | 0.41 |
Osteoarthritis | 2.6 | 0.2 | 12 |
Osteoporosis | 1.9 | 0.8 | 1.37 |
pancreatic cancer | 0.6 | 0.6 | |
Parkinson's Disease | 3.2 | 4.8 | -0.5 |
Polycystic ovary syndrome | 2.8 | 2 | 0.4 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.9 | -2 |
Premenstrual dysphoric disorder | 1.5 | 0.1 | 14 |
primary biliary cholangitis | 0.5 | 1.3 | -1.6 |
Psoriasis | 5 | 2.3 | 1.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.9 | 3.8 | 1.08 |
Rosacea | 1.7 | 0.8 | 1.13 |
Schizophrenia | 7.4 | 2.5 | 1.96 |
scoliosis | 0.5 | 1.3 | -1.6 |
Sjögren syndrome | 3.2 | 3.8 | -0.19 |
Sleep Apnea | 1.7 | 2.2 | -0.29 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1 | 0.1 |
Stress / posttraumatic stress disorder | 2.9 | 3.2 | -0.1 |
Systemic Lupus Erythematosus | 4.2 | 2.4 | 0.75 |
Tic Disorder | 1.5 | 2.3 | -0.53 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 4.4 | 3.4 | 0.29 |
Type 2 Diabetes | 9.1 | 7.7 | 0.18 |
Ulcerative colitis | 3.8 | 6.1 | -0.61 |
Unhealthy Ageing | 6.8 | 2.5 | 1.72 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.